StockMacro
Menu

Emergent Biosolutions

$5.05 -45% in 6 monthsMarket cap $259.6M

EBS on XNYS, Health Care, Emergent Biosolutions, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue fell 52% to $110M, but federal contracts rose to $277.6M over 12 months.

  • BadNet loss of $260.7M over 12 months on $649.1M revenue
  • BadShort sellers hold 20% of shares, 10.1 days to cover

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Industry
Pharmaceutical preparations (Health Care)
Employees
900
Website
emergentbiosolutions.com
Listed
NYSE, US
Last results
2 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $110.0M, net loss $32.7M.
Quarter to 31 Dec 2021: revenue $732.9M, net income $193.1MQuarter to 31 Dec 2021: revenue $732.9M, net income $193.1MQuarter to 31 Mar 2022: revenue $307.5M, net income -$3.7MQuarter to 31 Mar 2022: revenue $307.5M, net income -$3.7MQuarter to 30 Jun 2022: revenue $242.7M, net income -$56.4MQuarter to 30 Jun 2022: revenue $242.7M, net income -$56.4MQuarter to 30 Sep 2022: revenue $240.0M, net income -$75.7MQuarter to 30 Sep 2022: revenue $240.0M, net income -$75.7MQuarter to 31 Dec 2022: revenue $330.2M, net income -$67.0MQuarter to 31 Dec 2022: revenue $330.2M, net income -$67.0MQuarter to 31 Mar 2023: revenue $165.1M, net income -$183.0MQuarter to 31 Mar 2023: revenue $165.1M, net income -$183.0MQuarter to 30 Jun 2023: revenue $337.9M, net income -$261.3MQuarter to 30 Jun 2023: revenue $337.9M, net income -$261.3MQuarter to 30 Sep 2023: revenue $270.5M, net income -$263.4MQuarter to 30 Sep 2023: revenue $270.5M, net income -$263.4MQuarter to 31 Mar 2024: revenue $300.4M, net income $9.0MQuarter to 31 Mar 2024: revenue $300.4M, net income $9.0MQuarter to 30 Jun 2024: revenue $254.7M, net income -$283.1MQuarter to 30 Jun 2024: revenue $254.7M, net income -$283.1MQuarter to 30 Sep 2024: revenue $293.8M, net income $114.8MQuarter to 30 Sep 2024: revenue $293.8M, net income $114.8MQuarter to 31 Dec 2024: revenue $194.7M, net income –Quarter to 31 Mar 2025: revenue $222.2M, net income $68.0MQuarter to 31 Mar 2025: revenue $222.2M, net income $68.0MQuarter to 30 Jun 2025: revenue $140.9M, net income -$12.0MQuarter to 30 Jun 2025: revenue $140.9M, net income -$12.0MQuarter to 30 Sep 2025: revenue $231.1M, net income $51.2MQuarter to 30 Sep 2025: revenue $231.1M, net income $51.2MQuarter to 31 Dec 2025: revenue $148.7M, net income -$54.6MQuarter to 31 Dec 2025: revenue $148.7M, net income -$54.6MQuarter to 31 Mar 2026: revenue $156.1M, net income $6.8MQuarter to 31 Mar 2026: revenue $156.1M, net income $6.8MQuarter to 30 Jun 2026: revenue $234.3M, net income -$180.2MQuarter to 30 Jun 2026: revenue $234.3M, net income -$180.2MQuarter to 30 Sep 2026: revenue $110.0M, net income -$32.7MQuarter to 30 Sep 2026: revenue $110.0M, net income -$32.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $732.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$110.0M-$32.7M
30 Jun 2026$234.3M-$180.2M
31 Mar 2026$156.1M$6.8M
31 Dec 2025$148.7M-$54.6M
30 Sep 2025$231.1M$51.2M
30 Jun 2025$140.9M-$12.0M
31 Mar 2025$222.2M$68.0M
31 Dec 2024$194.7M–
30 Sep 2024$293.8M$114.8M
30 Jun 2024$254.7M-$283.1M
31 Mar 2024$300.4M$9.0M
30 Sep 2023$270.5M-$263.4M
30 Jun 2023$337.9M-$261.3M
31 Mar 2023$165.1M-$183.0M
31 Dec 2022$330.2M-$67.0M
30 Sep 2022$240.0M-$75.7M
30 Jun 2022$242.7M-$56.4M
31 Mar 2022$307.5M-$3.7M
31 Dec 2021$732.9M$193.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $649.1M $788.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -18% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$260.7M $75.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$5.02 $1.43
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 48.4% 54.5% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -27.7% 15.0% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -40.2% 9.6% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -58.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $188.4M $1.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $175.7M $245.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $514.3M $693.1M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $338.6M $447.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 1.6 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $6.09
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 0.40 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 0.92 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.83 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Emergent BiosolutionsEBS (this company) $259.6Mloss0.40-18%-40.2%
AltimmuneALT $258.8Mloss–––
Prelude TherapeuticsPRLD $258.5Mloss12.0+105%-247%
PepGenPEPG $261.8Mloss–––
Q32 BioQTTB $249.6M7.7–––
Standard BioToolsLAB $249.1M–3.0-22%158%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$146K

bought $0, sold $146K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-5.2%

183 13F filers vs 193

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

88%

45.2M shares held by 13F filers (30 Sep 2026) of 51.4M outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

20%

10.1M shares sold short (30 Oct 2026) of 51.4M outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.1

10.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.1%

9.7M shares sold short in the report before, 10.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

65%

65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

29

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-52%

$110.0M vs $231.1M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-2.9%

$3.3M vs $3.4M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$277.6M

the 12 months before: $243.8M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$2.1M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

7

7 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

7 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $5.05 on 20 Nov 2026, -44% over 12 months (12-month range $4.45 to $13.90)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $986K in the last 12 months (the 12 months before: -$671K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, 0% on the 12 months before.
Revenue per quarter. Revenue $110.0M in the latest quarter, -52% on a year earlier.
Capital spending per quarter. Capital spending $3.3M in the latest quarter, -2.9% on a year earlier.
Institutional holders (13F filers). 183 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Federal obligations. Federal obligations: $216.6M published in the last 12 months, -24% on the 12 months before.
Lobbying spend. Lobbying spend: $2.1M published in the last 12 months, -17% on the 12 months before.
Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Oct 2026Lobbying filinglobbying engagement terminated (THE NICKLES GROUP, LLC)
16 Oct 20268-K and other filingsDirector or officer change
5 Aug 20268-K and other filingsDirector or officer change
5 Aug 20268-K and other filingsRestructuring costs announced
5 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Jun 2026Sharp changeFederal obligations jump: federal obligations jump, 64.5M vs usual 323K in the same month of earlier years (2026-05-01..2026-05-31)
16 Apr 20268-K and other filingsA major agreement ended
7 Apr 2026Sharp changeFederal obligations jump: federal obligations jump, 53.7M vs usual 6.9M in the same month of earlier years (2026-03-01..2026-03-31); 7.7x the same month a year earlier
3 Mar 20268-K and other filingsDirector or officer change
3 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jan 2026Lobbying filinglobbying engagement terminated (ALPINE GROUP PARTNERS, LLC.)
12 Nov 20258-K and other filingsDirector or officer change
12 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Oct 2025Sharp changeFederal obligations jump: federal obligations jump, 55.0M vs usual 4.4M in the same month of earlier years (2025-09-01..2025-09-30); 154.1x the same month a year earlier
9 Sep 2025Sharp changeFederal obligations jump: federal obligations jump, 30.0M vs usual 2.0M in the same month of earlier years (2025-08-01..2025-08-31); 0.7x the same month a year earlier
14 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 140.9M vs usual 273.6M (2025-06-30); 0.6x the same period a year earlier
20 Jan 2025Lobbying filinglobbying engagement terminated (ERVIN GRAVES STRATEGY GROUP, LLC)
7 Jan 2025Sharp changeFederal obligations jump: federal obligations jump, 50.0M vs usual 683K in the same month of earlier years (2024-12-01..2024-12-31)
2 Dec 20248-K and other filingsRegistered new securities for sale (S-1)
12 Nov 20248-K and other filingsRegistered new securities for sale (S-1)
7 Nov 2024Lobbying filinglobbying engagement terminated (THE OB-C GROUP, LLC)
17 Oct 2024Lobbying filinglobbying engagement terminated (HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC)
4 Oct 20248-K and other filingsDirector or officer change
10 Sep 2024Sharp changeFederal obligations jump: federal obligations jump, 41.9M vs usual 2.0M in the same month of earlier years (2024-08-01..2024-08-31)
3 Sep 20248-K and other filingsA major agreement ended
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 44 vs usual 19.50 (2024-06-30); 2.6x the same period a year earlier
30 Jul 20248-K and other filingsDirector or officer change
12 Jul 20248-K and other filingsDirector or officer change
9 Jul 2024Sharp changeFederal obligations jump: federal obligations jump, 130.0M vs usual 7.4M in the same month of earlier years (2024-06-01..2024-06-30); 2.1x the same month a year earlier
29 May 20248-K and other filingsDirector or officer change
1 May 20248-K and other filingsRestructuring costs announced
26 Apr 20248-K and other filingsDirector or officer change
21 Feb 20248-K and other filingsDirector or officer change
21 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Jan 2024Lobbying filinglobbying engagement terminated (TODD STRATEGY GROUP)
12 Dec 2023Sharp changeFederal obligations jump: federal obligations jump, 75.0M vs usual 0 in the same month of earlier years (2023-11-01..2023-11-30)
24 Nov 20238-K and other filingsDelisting notice or listing transfer
19 Nov 2023Lobbying filingnew lobbying registration (TODD STRATEGY GROUP)
16 Nov 20238-K and other filingsEarlier financial statements can no longer be relied on
9 Nov 20238-K and other filingsReport will be filed late
17 Oct 2023Lobbying filinglobbying engagement terminated (FORBES-TATE)
2 Oct 20238-K and other filingsDirector or officer change
16 Aug 20238-K and other filingsDirector or officer change
9 Aug 2023WARN layoff noticeEmergent Biosolutions, Inc., 86 workers, Canton, MA
9 Aug 2023Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 86)
8 Aug 20238-K and other filingsDirector or officer change
8 Aug 20238-K and other filingsRestructuring costs announced
31 Jul 2023Sharp changeLobbying on a new issue: lobbying on a new issue: AER, AVI (2023-06-30)
27 Jul 20238-K and other filingsDirector or officer change
11 Jul 2023Sharp changeFederal obligations jump: federal obligations jump, 62.9M vs usual 7.4M in the same month of earlier years (2023-06-01..2023-06-30); 5.3x the same month a year earlier
27 Jun 20238-K and other filingsDirector or officer change
15 Jun 2023Lobbying filingnew lobbying registration (CGCN GROUP, LLC)
6 Jun 2023Sharp changeFederal obligations jump: federal obligations jump, 252.8M vs usual 23.7M in the same month of earlier years (2023-05-01..2023-05-31); 782.3x the same month a year earlier
31 May 20238-K and other filingsDirector or officer change
15 May 20238-K and other filingsCompleted an acquisition or asset sale
23 Mar 20238-K and other filingsDirector or officer change
14 Feb 2023Sharp changeShort interest spike: short interest spike, 5.6M vs usual 3.3M (2023-01-31); 1.5x the same period a year earlier
31 Jan 2023Sharp changeShort interest spike: short interest spike, 5.4M vs usual 3.3M (2023-01-13); 1.5x the same period a year earlier
17 Jan 2023Sharp changeShort interest spike: short interest spike, 5.6M vs usual 3.3M (2022-12-30); 2.0x the same period a year earlier
9 Jan 20238-K and other filingsDirector or officer change
9 Jan 20238-K and other filingsRestructuring costs announced
9 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 2022Lobbying filingnew lobbying registration (CAPITOL COUNSEL LLC)
26 Sep 20228-K and other filingsCompleted an acquisition or asset sale
6 Sep 2022Sharp changeFederal obligations jump: federal obligations jump, 18.3M vs usual 2.0M in the same month of earlier years (2022-08-01..2022-08-31); 9.0x the same month a year earlier
12 Jul 2022Sharp changeFederal obligations jump: federal obligations jump, 11.9M vs usual 1.2M in the same month of earlier years (2022-06-01..2022-06-30); 1.6x the same month a year earlier
6 Jul 20228-K and other filingsDirector or officer change
6 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Jun 20228-K and other filingsA major agreement ended
23 Mar 20228-K and other filingsDirector or officer change
22 Feb 20228-K and other filingsDirector or officer change
20 Jan 2022Lobbying filinglobbying engagement terminated (BLANK ROME GOVERNMENT RELATIONS)
18 Jan 2022Lobbying filinglobbying engagement terminated (NEXA STRATEGIES, LLC)
18 Jan 2022Lobbying filinglobbying engagement terminated (DOTCHIN & ASSOCIATES, LLC)
14 Jan 20228-K and other filingsDirector or officer change
14 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 May 2022: -$71K published
Month from 1 Jun 2022: -$37K published
Month from 1 Nov 2022: -$23K published
Month from 1 Jul 2023: -$30K published
Month from 1 May 2024: -$6K published
Month from 1 Jun 2024: -$70K published
Month from 1 Nov 2024: -$444K published
Month from 1 Mar 2025: -$261K published
Month from 1 May 2025: $300K published
Month from 1 Aug 2025: -$131K published
Month from 1 Oct 2025: -$306K published
Month from 1 Nov 2025: -$273K published
Month from 1 Dec 2025: -$263K published
Month from 1 Apr 2026: -$34K published
Month from 1 May 2026: -$518K published
Month from 1 Jul 2026: -$25K published
Month from 1 Oct 2026: -$146K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $732.9M, +26% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Mar 2022: $307.5M, -15% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $242.7M, -41% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $240.0M, -27% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $330.2M, -55% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Mar 2023: $165.1M, -46% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $337.9M, +39% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $270.5M, +13% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Mar 2024: $300.4M, +82% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $254.7M, -25% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $293.8M, +8.6% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $194.7M; public on 5 Mar 2025
Quarter ended 31 Mar 2025: $222.2M, -26% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $140.9M, -45% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $231.1M, -21% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $148.7M, -24% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $156.1M, -30% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $234.3M, +66% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $110.0M, -52% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $46.7M, +30% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $32.2M, -43% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $32.1M, -52% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $27.9M, -49% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $23.6M, -49% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $15.1M, -53% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $12.5M, -61% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $12.6M, -55% on a year earlier; public on 12 Dec 2023
Quarter ended 31 Dec 2023: $11.4M, -52% on a year earlier; public on 9 Mar 2024
Quarter ended 31 Mar 2024: $10.8M, -28% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $4.6M, -63% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $5.8M, -54% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $1.7M, -85% on a year earlier; public on 5 Mar 2025
Quarter ended 31 Mar 2025: $3.6M, -67% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $2.9M, -37% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $3.4M, -41% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $3.9M, +129% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $2.4M, -33% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $2.1M, -28% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $3.3M, -2.9% on a year earlier; public on 4 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 232; public on 14 Feb 2022
31 Mar 2022 report: 236; public on 16 May 2022
30 Jun 2022 report: 218; public on 15 Aug 2022
30 Sep 2022 report: 183; public on 14 Nov 2022
31 Dec 2022 report: 179; public on 14 Feb 2023
31 Mar 2023 report: 181; public on 15 May 2023
30 Jun 2023 report: 169; public on 14 Aug 2023
30 Sep 2023 report: 149; public on 14 Nov 2023
31 Dec 2023 report: 122; public on 14 Feb 2024
31 Mar 2024 report: 116; public on 15 May 2024
30 Jun 2024 report: 132; public on 14 Aug 2024
30 Sep 2024 report: 134; public on 14 Nov 2024
31 Dec 2024 report: 151; public on 14 Feb 2025
31 Mar 2025 report: 158; public on 15 May 2025
30 Jun 2025 report: 154; public on 14 Aug 2025
30 Sep 2025 report: 164; public on 14 Nov 2025
31 Dec 2025 report: 179; public on 17 Feb 2026
31 Mar 2026 report: 182; public on 15 May 2026
30 Jun 2026 report: 193; public on 14 Aug 2026
30 Sep 2026 report: 183; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $0 published
Month from 1 Dec 2021: $2.1M published
Month from 1 Jan 2022: $653K published
Month from 1 Feb 2022: -$4.4M published
Month from 1 Mar 2022: $156K published
Month from 1 Apr 2022: -$111.9M published
Month from 1 May 2022: $216K published
Month from 1 Jun 2022: $11.8M published
Month from 1 Jul 2022: $17.7M published
Month from 1 Aug 2022: $18.3M published
Month from 1 Sep 2022: $1.9M published
Month from 1 Oct 2022: $6.6M published
Month from 1 Nov 2022: $0 published
Month from 1 Dec 2022: $538K published
Month from 1 Jan 2023: $6.8M published
Month from 1 Feb 2023: $0 published
Month from 1 Mar 2023: $476K published
Month from 1 Apr 2023: $4.8M published
Month from 1 May 2023: $252.8M published
Month from 1 Jun 2023: $62.8M published
Month from 1 Jul 2023: -$5.7M published
Month from 1 Aug 2023: $60.0M published
Month from 1 Sep 2023: $20K published
Month from 1 Oct 2023: $0 published
Month from 1 Nov 2023: $75.0M published
Month from 1 Dec 2023: -$4.2M published
Month from 1 Jan 2024: $0 published
Month from 1 Feb 2024: $0 published
Month from 1 Apr 2024: $6.5M published
Month from 1 May 2024: $6.9M published
Month from 1 Jun 2024: $7.8M published
Month from 1 Jul 2024: $130.0M published
Month from 1 Aug 2024: $0 published
Month from 1 Sep 2024: $42.3M published
Month from 1 Oct 2024: -$1.1M published
Month from 1 Dec 2024: $50.0M published
Month from 1 Jan 2025: $16.7M published
Month from 1 Mar 2025: $6.7M published
Month from 1 Apr 2025: $6.9M published
Month from 1 May 2025: $0 published
Month from 1 Jun 2025: $69.3M published
Month from 1 Jul 2025: $51.9M published
Month from 1 Sep 2025: $85.0M published
Month from 1 Dec 2025: $0 published
Month from 1 Feb 2026: $0 published
Month from 1 Mar 2026: $53.7M published
Month from 1 Apr 2026: $14.4M published
Month from 1 May 2026: $11K published
Month from 1 Jun 2026: $71.7M published
Month from 1 Jul 2026: $52.8M published
Month from 1 Aug 2026: $24.0M published
Lobbying spend
Quarter from 1 Jan 2022: $550K published
Quarter from 1 Apr 2022: $1.0M published
Quarter from 1 Jul 2022: $590K published
Quarter from 1 Oct 2022: $520K published
Quarter from 1 Jan 2023: $640K published
Quarter from 1 Apr 2023: $900K published
Quarter from 1 Jul 2023: $720K published
Quarter from 1 Oct 2023: $450K published
Quarter from 1 Jan 2024: $500K published
Quarter from 1 Apr 2024: $760K published
Quarter from 1 Jul 2024: $460K published
Quarter from 1 Oct 2024: $500K published
Quarter from 1 Jan 2025: $650K published
Quarter from 1 Apr 2025: $920K published
Quarter from 1 Jul 2025: $440K published
Quarter from 1 Oct 2025: $530K published
Quarter from 1 Jan 2026: $430K published
Quarter from 1 Apr 2026: $730K published
Quarter from 1 Jul 2026: $510K published
Quarter from 1 Oct 2026: $450K published
Workers in WARN layoff notices
Month from 1 Aug 2023: 86 published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $110.0M (30 Sep 2026), 47% below its normal quarter of $208.4M; higher than 31% of its own history.
  • Federal obligations jump: booked $64.5M in federal contract and grant obligations in May 2026, against none in the same month last year Public on 2 Jun 2026.
  • Insider net buying (open market): Insiders sold a net $986K in the last 12 months (the 12 months before: -$671K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months, 0% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 2 sales, $146K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
7 Oct 2026Donald W DeGolyerDirectorSellplanned in advance (10b5-1)17,800$7.09$126KForm 4
5 Oct 2026Paul Anthony WilliamsSVP, Products BusinessSellplanned in advance (10b5-1)3,000$6.53$20KForm 4
2 Jul 2026Paul Anthony WilliamsSVP, Products BusinessSellplanned in advance (10b5-1)3,000$8.40$25KForm 4
4 May 2026Kathryn C ZoonDirectorSellplanned in advance (10b5-1)17,202$8.40$144KForm 4
4 May 2026Donald W DeGolyerDirectorSellplanned in advance (10b5-1)15,481$8.40$130KForm 4
4 May 2026Keith KatkinDirectorSellplanned in advance (10b5-1)15,481$8.28$128KForm 4
4 May 2026Sujata Tyagi DayalDirectorSellplanned in advance (10b5-1)13,761$8.40$116KForm 4
3 Apr 2026Paul Anthony WilliamsSVP, Products BusinessSellplanned in advance (10b5-1)4,000$8.44$34KForm 4

183 institutions reported shares at the end of Q3 2026, 88% of the shares outstanding; 30 opened a position, 39 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.5.2M10.1%$34.1M+453K+9.6%
American Century Companies Inc3.3M6.44%$21.9M+542K+20%
State Street Corp2.7M5.28%$17.9M-216K-7.4%
Dimensional Fund Advisors LP2.6M4.99%$16.9M-510K-17%
Vanguard Capital Management LLC2.2M4.20%$14.3M-38K-1.7%
LSV Asset Management2.0M3.87%+294K+17%
Acadian Asset Management LLC1.9M3.76%+589K+44%
Millennium Management LLC1.9M3.66%$12.4M+809K+75%
Oak Hill Advisors LP1.5M2.94%$10.0M+401K+36%
Geode Capital Management, LLC1.3M2.47%$8.4M-66K-4.9%

Federal contracts

All 29 federal contracts

1 new award in 12 months, $21.5M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
8 Jan 2026Department of DefenseDepartment of the Army$21.5Mup to $66.9MFOR THE PROCUREMENT OF BIOTHRAX (ANTHRAX VACCINE ABSORBED (AVA))USAspending
19 Jan 2024Department of DefenseDepartment of the Army$21.0Mup to $41.8MPROCUREMENT OF BIOTHRAX (ANTHRAX VACCINE ADSORBED)USAspending
31 Jul 2023Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$60.0Mup to $704.2MMEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKINUSAspending
19 Sep 2022Department of State$1.8MSKIN DECONTAMINATION LOTIONUSAspending
23 Jul 2020Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$20.0MTO EXPAND THE PUBLIC-PRIVATE PARTNERSHIP WITH EMERGENT TO RESERVE THE CAPACITIES AND CAPABILITIES AT CONTRACTOR?S BAYVIEW CIADM FACILITY.USAspending
24 May 2020Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$628.2MEMERGENT CIADM MANUFACTURING CAPACITY RESERVATION AND EXPANSIONUSAspending
2 Apr 2020Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$14.5Mup to $22.2MDEVELOPMENT OF A PLASMA-DERIVED POLYCLONAL ANTIBODY-BASED COVID-19 THERAPEUTICUSAspending
30 Sep 2019Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$50.0MBOTULISM ANTITOXINUSAspending

Company events

All 93 company events

In 12 months: 3 director or officer changes, 2 major agreements, 1 agreement ended, 1 restructuring. Results releases and routine reports are left out.

FiledWhat happenedSource
16 Oct 2026Director or officer change8-K
5 Aug 2026Director or officer change; Restructuring costs announced8-K
29 Jun 2026Signed a major agreement8-K
16 Apr 2026Signed a major agreement; A major agreement endedSame filing: sold shares privately8-K
3 Mar 2026Director or officer change8-K
12 Nov 2025Director or officer change8-K
11 Sep 2025Signed a major agreement8-K
2 Dec 2024Registered new securities for sale (S-1)S-1/A

29 open postings; careers site tracked since 21 Nov 2026. Most in Manufacturing & production 24%, Test, quality & reliability 17%, Finance & accounting 10%, Process engineering (semiconductor / materials) 10%.

PostedJobLocation
21 Nov 2026or earlierTERM - Sr Specialist, Env, Health & Safety-WINFacilities & constructionWinnipeg, MB, CA, R3T 5Y3
21 Nov 2026or earlierHead of IT Infrastructure & Operations, Sr. Director (remote)Corporate ITGaithersburg, MD, US, 20879
21 Nov 2026or earlierVP, Strategic Manufacturing ServicesManufacturing & productionGaithersburg, MD, US, 20879
21 Nov 2026or earlierSr Engineer, ProcessSoftware engineeringCanton, MA, US, 02021
21 Nov 2026or earlierSr BioProcess AssociateManufacturing & productionCanton, MA, US, 02021
21 Nov 2026or earlierBioProcess AssociateManufacturing & productionCanton, MA, US, 02021
21 Nov 2026or earlierMetrology TechnicianProcess engineering (semiconductor / materials)Canton, MA, US, 02021
21 Nov 2026or earlierAdministrative AssistantExecutive & administrative supportCanton, MA, US, 02021

Reported lobbying spend: $450K in Q3 2026, $510K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Aug 2026EndedThe Nickles Group, LLCfor Emergent BiosolutionsFunding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.; Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxon; S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.Budget, Health issues, DefenseFiling
31 Dec 2025EndedAlpine Group Partners, LLC.for Emergent BiosolutionsReauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation,Health issues, AviationFiling
31 Dec 2024EndedErvin Graves Strategy Group, LLCfor Emergent Biosolutions Inc.Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25; Opioid and heroin addictDISFiling
31 Aug 2024EndedThe Ob-C Group, LLCfor Emergent Biosolutions Inc.* Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act * No Specific Bill Number. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield * No SBudget, DIS, Defense, Health issuesFiling
31 Aug 2024EndedHecht Latham Spencer & Associates, Inc., Formerly Known As Hecht Spencer & Assocfor Emergent BiosolutionsDraft - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 - Title II - Department of Health and Human Services - funding and policy for development, acquisition, and procurement of medical countermeasures for the Strategic National StockpilHomeland security, DIS, Budget, Health issuesFiling
31 Jul 2023EndedForbes-Tatefor Emergent BiosolutionsIssues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, Further Extending Government Funding Act (PL 117-70); Issues related to the development, manufacture, and distribution of coronavir; Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); HHealth issues, BudgetFiling
1 Jul 2023EndedTodd Strategy Groupfor Emergent Biosolutions Inc.Not statedFiling
1 Jul 2023NewTodd Strategy Groupfor Emergent Biosolutions Inc.Health Care Supply Chain. Strategic National Stockpile. PAHPA. Implementation of Inflation Reduction Act.Health issuesFiling

Layoff notices

All 1 layoff notices

No notice in 12 months; the latest is dated 8 Aug 2023. State WARN notices.

NoticeSiteWorkersJobs endSource
8 Aug 2023Emergent Biosolutions, Inc.Canton, MA867 Oct 2023Notice

The 5 newest of 138 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

9 Sep 2025confirmed

Confirmed across sources Government contracts and Filings + Financials

Emergent Biosolutions (EBS): reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year, while it booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year. Two unrelated kinds of activity within 56 days.

  • Financials: Quarterly revenue change, became public on 14 Aug 2025
  • Government contracts: Federal obligations jump, became public on 4 Sep 2025
  • Government contracts: Federal obligations jump, became public on 30 Sep 2025
2023-06-30: $337.9M2023-09-30: $270.5M2023-12-31: $276.6M2024-03-31: $300.4M2024-06-30: $254.7M2024-09-30: $293.8M2024-12-31: $194.7M2025-03-31: $222.2M2025-06-30: $140.9M
The quarter ended 30 Jun 2025 against the 8 quarters before it. this quarterearliernormal: $273.6M
See the evidence (3 changes)

Financials: Quarterly revenue change became public on 14 Aug 2025

Emergent Biosolutions reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year.

This period
$140.9M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$273.6M
Typical spread (median absolute deviation)
$23.6M
How far from its usual level
-3.8
Same quarter last year
$254.7M
History used
3,378 days
2023-06-30: $337.9M2023-09-30: $270.5M2023-12-31: $276.6M2024-03-31: $300.4M2024-06-30: $254.7M2024-09-30: $293.8M2024-12-31: $194.7M2025-03-31: $222.2M2025-06-30: $140.9M
the quarter ended 30 Jun 20258 earlier quartersnormal: $273.6M

Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Government contracts: Federal obligations jump became public on 4 Sep 2025

Emergent Biosolutions booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year.

This period
$30.0M (August 2025)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+9.2
Same month last year
$41.9M
History used
6,467 days
2020-08-01: $843K2021-08-01: $2.0M2022-08-01: $18.3M2023-08-01: $02024-08-01: $41.9M2025-08-01: $30.0M
August 20255 earlier monthsnormal: $2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Government contracts: Federal obligations jump became public on 30 Sep 2025

Emergent Biosolutions booked $55.0M in federal contract and grant obligations in September 2025, 154× the same month last year.

This period
$55.0M (September 2025)
Normal month (median of 4 earlier)
$4.4M
Typical spread (median absolute deviation)
$6.4M
How far from its usual level
+5.4
Same month last year
$357K
History used
1,819 days
2021-09-01: $404.3M2022-09-01: $8.5M2023-09-01: $02024-09-01: $357K2025-09-01: $55.0M
September 20254 earlier monthsnormal: $4.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

10 Sep 2024confirmed

Confirmed across sources Government contracts and Institutional holdings

Emergent Biosolutions (EBS): saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year, while it booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year. Two unrelated kinds of activity within 21 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
  • Government contracts: Federal obligations jump, became public on 5 Sep 2024
2022-06-30: 182022-09-30: 212022-12-31: 242023-03-31: 282023-06-30: 172023-09-30: 212023-12-31: 132024-03-31: 182024-06-30: 44
The quarter ended 30 Jun 2024 against the 8 quarters before it. this quarterearliernormal: 19.5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

Emergent Biosolutions saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year.

This period
44 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
19.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
17
History used
3,926 days
2022-06-30: 182022-09-30: 212022-12-31: 242023-03-31: 282023-06-30: 172023-09-30: 212023-12-31: 132024-03-31: 182024-06-30: 44
the quarter ended 30 Jun 20248 earlier quartersnormal: 19.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Government contracts: Federal obligations jump became public on 5 Sep 2024

Emergent Biosolutions booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year.

This period
$41.9M (August 2024)
Normal month (median of 5 earlier)
$2.0M
Typical spread (median absolute deviation)
$2.0M
How far from its usual level
+13.2
Same month last year
$0
History used
6,102 days
2019-08-01: $172.2M2020-08-01: $843K2021-08-01: $2.0M2022-08-01: $18.3M2023-08-01: $02024-08-01: $41.9M
August 20245 earlier monthsnormal: $2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

31 Jul 2023confirmed

Confirmed across sources Government contracts and Layoff notices and Lobbying

Emergent Biosolutions (EBS): booked $62.9M in federal contract and grant obligations in June 2023, 5.3× the same month last year; it also lobbying on a new issue; and it filed a WARN layoff notice covering 86 workers within 30 days (Canton, MA). Three unrelated kinds of activity within 28 days.

  • Government contracts: Federal obligations jump, became public on 22 Jun 2023
  • Lobbying: Lobbying on a new issue, became public on 31 Jul 2023
  • Layoff notices: WARN layoff notice, became public on 9 Aug 2023
2018-06-01: $82.2M2019-06-01: $427K2020-06-01: $1.2M2021-06-01: $7.4M2022-06-01: $11.9M2023-06-01: $62.9M
June 2023 against the 5 months before it. this monthearliernormal: $7.4M
See the evidence (3 changes)

Government contracts: Federal obligations jump became public on 22 Jun 2023

Emergent Biosolutions booked $62.9M in federal contract and grant obligations in June 2023, 5.3× the same month last year.

This period
$62.9M (June 2023)
Normal month (median of 5 earlier)
$7.4M
Typical spread (median absolute deviation)
$6.2M
How far from its usual level
+6.0
Same month last year
$11.9M
History used
5,674 days
2018-06-01: $82.2M2019-06-01: $427K2020-06-01: $1.2M2021-06-01: $7.4M2022-06-01: $11.9M2023-06-01: $62.9M
June 20235 earlier monthsnormal: $7.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Lobbying: Lobbying on a new issue became public on 31 Jul 2023

Emergent Biosolutions lobbying on a new issue.

New
['AER', 'AVI']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12621074

Layoff notices: WARN layoff notice became public on 9 Aug 2023

Emergent Biosolutions filed a WARN layoff notice covering 86 workers within 30 days (Canton, MA).

Notices in the window
1
Workers named
86
Window
10 Jul 2023 to 9 Aug 2023

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Oct 2026Lobbying record

    EMERGENT BIOSOLUTIONS: lobbying engagement terminated (THE NICKLES GROUP, LLC) (dated 31 Aug 2026)

  2. 16 Oct 2026Filings record

    Director or officer change

  3. 5 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 5 Aug 2026Filings record

    Director or officer change

  5. 5 Aug 2026Filings record

    Restructuring costs announced

  6. 2 Jun 2026Government contracts change

    booked $64.5M in federal contract and grant obligations in May 2026, against none in the same month last year.

    See the evidence
    This period
    $64.5M (May 2026)
    Normal month (median of 5 earlier)
    $323K
    Typical spread (median absolute deviation)
    $323K
    How far from its usual level
    +64.2
    Same month last year
    $0
    History used
    6,740 days
    2021-05-01: $58.0M2022-05-01: $323K2023-05-01: $252.8M2024-05-01: $235K2025-05-01: $02026-05-01: $64.5M
    May 20265 earlier monthsnormal: $323K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  7. 16 Apr 2026Filings record

    A major agreement ended

  8. 10 Apr 2026Government contracts record

    EMERGENT BIODEFENSE OPERATIONS LANSING LLC: new Department of Defense contract W911SR26FA005 ($7.2M) (dated 8 Jan 2026)

  9. 5 Apr 2026Government contracts change

    booked $53.7M in federal contract and grant obligations in March 2026, 7.7× the same month last year.

    Same month last year: $6.9M; its normal month is $6.9M.

    See the evidence
    This period
    $53.7M (March 2026)
    Normal month (median of 5 earlier)
    $6.9M
    Typical spread (median absolute deviation)
    $6.7M
    How far from its usual level
    +4.7
    Same month last year
    $6.9M
    History used
    6,679 days
    2021-03-01: $29.8M2022-03-01: $187K2023-03-01: $02024-03-01: $7.8M2025-03-01: $6.9M2026-03-01: $53.7M
    March 20265 earlier monthsnormal: $6.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  10. 3 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 3 Mar 2026Filings record

    Director or officer change

  12. 17 Jan 2026Lobbying record

    EMERGENT BIOSOLUTIONS: lobbying engagement terminated (ALPINE GROUP PARTNERS, LLC.) (dated 31 Dec 2025)

  13. 12 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 12 Nov 2025Filings record

    Director or officer change

  15. 30 Sep 2025Government contracts change

    booked $55.0M in federal contract and grant obligations in September 2025, 154× the same month last year.

    Same month last year: $357K; its normal month is $4.4M.

    See the evidence
    This period
    $55.0M (September 2025)
    Normal month (median of 4 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $6.4M
    How far from its usual level
    +5.4
    Same month last year
    $357K
    History used
    1,819 days
    2021-09-01: $404.3M2022-09-01: $8.5M2023-09-01: $02024-09-01: $357K2025-09-01: $55.0M
    September 20254 earlier monthsnormal: $4.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  16. 9 Sep 2025several at once

    reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year, while it booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year. Two unrelated kinds of activity within 56 days.

    See the evidence (3 changes)

    Financials: Quarterly revenue change became public on 14 Aug 2025

    Emergent Biosolutions reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year.

    This period
    $140.9M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $273.6M
    Typical spread (median absolute deviation)
    $23.6M
    How far from its usual level
    -3.8
    Same quarter last year
    $254.7M
    History used
    3,378 days
    2023-06-30: $337.9M2023-09-30: $270.5M2023-12-31: $276.6M2024-03-31: $300.4M2024-06-30: $254.7M2024-09-30: $293.8M2024-12-31: $194.7M2025-03-31: $222.2M2025-06-30: $140.9M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $273.6M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Government contracts: Federal obligations jump became public on 4 Sep 2025

    Emergent Biosolutions booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year.

    This period
    $30.0M (August 2025)
    Normal month (median of 5 earlier)
    $2.0M
    Typical spread (median absolute deviation)
    $2.0M
    How far from its usual level
    +9.2
    Same month last year
    $41.9M
    History used
    6,467 days
    2020-08-01: $843K2021-08-01: $2.0M2022-08-01: $18.3M2023-08-01: $02024-08-01: $41.9M2025-08-01: $30.0M
    August 20255 earlier monthsnormal: $2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

    Government contracts: Federal obligations jump became public on 30 Sep 2025

    Emergent Biosolutions booked $55.0M in federal contract and grant obligations in September 2025, 154× the same month last year.

    This period
    $55.0M (September 2025)
    Normal month (median of 4 earlier)
    $4.4M
    Typical spread (median absolute deviation)
    $6.4M
    How far from its usual level
    +5.4
    Same month last year
    $357K
    History used
    1,819 days
    2021-09-01: $404.3M2022-09-01: $8.5M2023-09-01: $02024-09-01: $357K2025-09-01: $55.0M
    September 20254 earlier monthsnormal: $4.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  17. 4 Sep 2025Government contracts change

    booked $30.0M in federal contract and grant obligations in August 2025, 28% below the same month last year.

    Same month last year: $41.9M; its normal month is $2.0M.

    See the evidence
    This period
    $30.0M (August 2025)
    Normal month (median of 5 earlier)
    $2.0M
    Typical spread (median absolute deviation)
    $2.0M
    How far from its usual level
    +9.2
    Same month last year
    $41.9M
    History used
    6,467 days
    2020-08-01: $843K2021-08-01: $2.0M2022-08-01: $18.3M2023-08-01: $02024-08-01: $41.9M2025-08-01: $30.0M
    August 20255 earlier monthsnormal: $2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  18. 14 Aug 2025Financials change

    reported revenue of $140.9M for the quarter ended 30 Jun 2025, 45% below the same quarter last year.

    Same quarter last year: $254.7M; its normal quarter is $273.6M.

    See the evidence
    This period
    $140.9M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $273.6M
    Typical spread (median absolute deviation)
    $23.6M
    How far from its usual level
    -3.8
    Same quarter last year
    $254.7M
    History used
    3,378 days
    2023-06-30: $337.9M2023-09-30: $270.5M2023-12-31: $276.6M2024-03-31: $300.4M2024-06-30: $254.7M2024-09-30: $293.8M2024-12-31: $194.7M2025-03-31: $222.2M2025-06-30: $140.9M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $273.6M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  19. 16 May 2025Insiders record

    PAPA JOSEPH C (President and CEO) bought 60,000 shares of EBS ($349,800) (dated 15 May 2025)

  20. 20 Jan 2025Lobbying record

    EMERGENT BIOSOLUTIONS INC.: lobbying engagement terminated (ERVIN GRAVES STRATEGY GROUP, LLC) (dated 31 Dec 2024)

  21. 25 Dec 2024Government contracts change

    booked $50.0M in federal contract and grant obligations in December 2024, against none in the same month last year.

    See the evidence
    This period
    $50.0M (December 2024)
    Normal month (median of 5 earlier)
    $683K
    Typical spread (median absolute deviation)
    $683K
    How far from its usual level
    +48.7
    Same month last year
    $0
    History used
    6,224 days
    2019-12-01: $5.0M2020-12-01: $683K2021-12-01: $1.4M2022-12-01: $532K2023-12-01: $02024-12-01: $50.0M
    December 20245 earlier monthsnormal: $683K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  22. 2 Dec 2024Filings record

    Registered new securities for sale (S-1)

  23. 12 Nov 2024Filings record

    Registered new securities for sale (S-1)

  24. 7 Nov 2024Lobbying record

    EMERGENT BIOSOLUTIONS INC.: lobbying engagement terminated (THE OB-C GROUP, LLC) (dated 31 Aug 2024)

  25. 17 Oct 2024Lobbying record

    EMERGENT BIOSOLUTIONS: lobbying engagement terminated (HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC) (dated 31 Aug 2024)

  26. 4 Oct 2024Filings record

    Director or officer change

  27. 10 Sep 2024several at once

    saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year, while it booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year. Two unrelated kinds of activity within 21 days.

    See the evidence (2 changes)

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

    Emergent Biosolutions saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year.

    This period
    44 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    19.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.2
    Same quarter last year
    17
    History used
    3,926 days
    2022-06-30: 182022-09-30: 212022-12-31: 242023-03-31: 282023-06-30: 172023-09-30: 212023-12-31: 132024-03-31: 182024-06-30: 44
    the quarter ended 30 Jun 20248 earlier quartersnormal: 19.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Government contracts: Federal obligations jump became public on 5 Sep 2024

    Emergent Biosolutions booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year.

    This period
    $41.9M (August 2024)
    Normal month (median of 5 earlier)
    $2.0M
    Typical spread (median absolute deviation)
    $2.0M
    How far from its usual level
    +13.2
    Same month last year
    $0
    History used
    6,102 days
    2019-08-01: $172.2M2020-08-01: $843K2021-08-01: $2.0M2022-08-01: $18.3M2023-08-01: $02024-08-01: $41.9M
    August 20245 earlier monthsnormal: $2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  28. 5 Sep 2024Government contracts change

    booked $41.9M in federal contract and grant obligations in August 2024, against none in the same month last year.

    See the evidence
    This period
    $41.9M (August 2024)
    Normal month (median of 5 earlier)
    $2.0M
    Typical spread (median absolute deviation)
    $2.0M
    How far from its usual level
    +13.2
    Same month last year
    $0
    History used
    6,102 days
    2019-08-01: $172.2M2020-08-01: $843K2021-08-01: $2.0M2022-08-01: $18.3M2023-08-01: $02024-08-01: $41.9M
    August 20245 earlier monthsnormal: $2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  29. 3 Sep 2024Filings record

    A major agreement ended

  30. 14 Aug 2024Institutional holdings change

    saw 44 13F filers open a new position in the quarter ended 30 Jun 2024, 2.6× the same quarter last year.

    Same quarter last year: 17; its normal quarter is 19.5.

    See the evidence
    This period
    44 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    19.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.2
    Same quarter last year
    17
    History used
    3,926 days
    2022-06-30: 182022-09-30: 212022-12-31: 242023-03-31: 282023-06-30: 172023-09-30: 212023-12-31: 132024-03-31: 182024-06-30: 44
    the quarter ended 30 Jun 20248 earlier quartersnormal: 19.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  31. 30 Jul 2024Filings record

    Director or officer change

  32. 12 Jul 2024Filings record

    Director or officer change

  33. 4 Jul 2024Government contracts change

    booked $130.0M in federal contract and grant obligations in June 2024, 2.1× the same month last year.

    Same month last year: $62.9M; its normal month is $7.4M.

    See the evidence
    This period
    $130.0M (June 2024)
    Normal month (median of 5 earlier)
    $7.4M
    Typical spread (median absolute deviation)
    $6.2M
    How far from its usual level
    +13.3
    Same month last year
    $62.9M
    History used
    6,040 days
    2019-06-01: $427K2020-06-01: $1.2M2021-06-01: $7.4M2022-06-01: $11.9M2023-06-01: $62.9M2024-06-01: $130.0M
    June 20245 earlier monthsnormal: $7.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  34. 29 May 2024Filings record

    Director or officer change

  35. 1 May 2024Filings record

    Restructuring costs announced

  36. 26 Apr 2024Filings record

    Director or officer change

  37. 20 Apr 2024Government contracts record

    EMERGENT BIODEFENSE OPERATIONS LANSING LLC: new Department of Defense contract W911SR24F0016 ($6.5M) (dated 19 Jan 2024)

  38. 21 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 21 Feb 2024Filings record

    Director or officer change

  40. 23 Jan 2024Lobbying record

    EMERGENT BIOSOLUTIONS INC.: lobbying engagement terminated (TODD STRATEGY GROUP) (dated 1 Jul 2023)

Showing the newest 40 of 177 entries; narrow the window or the kind of data to see older ones.

Not listed: 342 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001367644
Ticker
EBS
Domain
emergentbiosolutions.com
Employer name
Emergent BioDefense Operations Lansing LLC, Emergent BioSolutions Inc., Emergent Product Development Gaithersburg Inc. (3 unverified)
Fein
16-1666785, 38-3412788 (2 unverified)
Hq location
MD|GAITHERSBURG|20879 (1 unverified)
Lobbying client
dotchin and associates on behalf of emergent biosolutions, emergent biosolutions, emergent biosolutions fka paxvax, emergent biosolutions formerly bracco diagnotics and 2 more
Name
400 Professional LLC, Cangene bioPharma LLC, Domestic, Emergent Acquisition Unlimited Company and 18 more
Uei
DKEFA8JAW3X4, M7ZHZ4P2MDG4, XM23STFMVML6
Wikipedia
Emergent BioSolutions
  • DOL H-1B labor condition applications and PERM certifications38 data points28 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)57 records, 278 data points30 Jun 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)235 records4 Jan 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1192 data points31 Dec 2008 to 26 Oct 2026
  • SEC Form 4 insider transactions170 records, 536 data points4 Jan 2016 to 7 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards29 records, 1654 data points17 Dec 2007 to 18 Aug 2026
  • WARN layoff notices (state labor agencies)1 record, 3 data points7 Aug 2023 to 8 Aug 2023
  • Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026